June 2019

The investigational candidate is the subject of a phase 3 study assessing efficacy and safety in adults with hATTR amyloidosis with transthyretin mutation.

The neurological symptoms of migraine aura are generally attributed to cortical spreading depression/depolarization, although that hypothesis does have its detractors. The question of whether CSD triggers migraine headache remains controversial.

Preclinical trials and success stories suggest that much is riding on vector-based therapies for the treatment of rare neurological conditions.

VMAT2, given its role in presynaptic packaging, storage, and release of dopamine, has emerged as a promising target for therapeutic interventions to manage movement disorders.

A lot of hype and hope surround this treatment class, making reasonable expectations difficult to form for practitioners and patients alike.

Sleep apnea and other sleep disorders are increasingly being recognized as major factors in the etiology and treatment of a host of neurological diseases, but awareness in the neurology community still has room to grow.

The head of the Cleveland Clinic stroke program and medical director of the Comprehensive Stroke Center sat down with Neurology Live for an in-depth discussion on stroke certifications, advanced treatment technology, and the ever-evolving concept of "time is brain."